NCT02712112View on ClinicalTrials.gov

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 16, 2016

Primary Completion Date

June 15, 2019

Study Completion Date

June 15, 2019

Conditions
Gastrointestinal Stromal Tumors (GISTs)
Interventions
DRUG

Imatinib Mesylate

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER